CRIS Current Research Information System

DERENZINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.347
AS - Asia 3.437
EU - Europa 2.796
AF - Africa 181
SA - Sud America 169
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.940
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.288
VN - Vietnam 1.025
SG - Singapore 951
CN - Cina 784
GB - Regno Unito 695
SE - Svezia 485
DE - Germania 365
IT - Italia 330
HK - Hong Kong 231
IN - India 172
FR - Francia 162
RU - Federazione Russa 146
BR - Brasile 111
IE - Irlanda 100
UA - Ucraina 93
NL - Olanda 83
CH - Svizzera 79
ZA - Sudafrica 65
BD - Bangladesh 62
EE - Estonia 61
FI - Finlandia 59
JP - Giappone 56
TG - Togo 47
CA - Canada 34
PL - Polonia 28
BG - Bulgaria 25
CI - Costa d'Avorio 24
PH - Filippine 20
HR - Croazia 19
KR - Corea 19
NG - Nigeria 18
AR - Argentina 16
BE - Belgio 16
IQ - Iraq 13
IR - Iran 13
TH - Thailandia 12
ES - Italia 11
ID - Indonesia 11
JO - Giordania 11
MX - Messico 11
GR - Grecia 10
CL - Cile 9
EC - Ecuador 9
AT - Austria 8
LB - Libano 7
TR - Turchia 7
TW - Taiwan 7
LT - Lituania 6
PY - Paraguay 6
SC - Seychelles 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
MY - Malesia 5
PE - Perù 5
VE - Venezuela 5
AU - Australia 4
CO - Colombia 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
ET - Etiopia 4
KE - Kenya 4
PK - Pakistan 4
SA - Arabia Saudita 4
BO - Bolivia 3
HU - Ungheria 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
TN - Tunisia 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
CR - Costa Rica 2
GE - Georgia 2
GT - Guatemala 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BY - Bielorussia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EU - Europa 1
GH - Ghana 1
HT - Haiti 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
SV - El Salvador 1
TM - Turkmenistan 1
UY - Uruguay 1
Totale 10.940
Salva come PNG Salva come JPEG
Città #
Singapore 637
Southend 605
Ashburn 450
Fairfield 448
Chandler 344
Dong Ket 310
Woodbridge 228
Houston 223
Hong Kong 214
Wilmington 203
Seattle 192
San Jose 179
Ann Arbor 173
Santa Clara 167
Ho Chi Minh City 150
Princeton 141
Cambridge 133
Hanoi 128
Beijing 124
Dublin 100
Boardman 97
Bern 75
Nanjing 73
New York 66
Westminster 63
Los Angeles 61
Padova 60
Lauterbourg 56
Helsinki 53
Tokyo 48
Lomé 47
Bologna 45
Jacksonville 45
Berlin 43
Dallas 42
Jinan 40
Hefei 36
Changsha 35
Council Bluffs 34
Frankfurt am Main 32
San Diego 32
Buffalo 28
Florence 28
Shenyang 28
Saint Petersburg 27
Hebei 26
Bremen 25
Abidjan 24
Sofia 24
São Paulo 23
Haiphong 22
Redondo Beach 22
Hyderabad 21
Milan 21
Turin 21
Warsaw 21
Redwood City 19
Toronto 19
Chicago 18
Jiaxing 17
Medford 17
Munich 17
Abeokuta 16
London 16
Phoenix 16
Shanghai 16
Brussels 15
Da Nang 15
Dearborn 15
Guangzhou 15
Ningbo 15
Norwalk 15
Zhengzhou 14
Mülheim 13
Nanchang 13
Redmond 13
San Francisco 13
Hangzhou 12
Seoul 12
Taizhou 12
Amman 11
Biên Hòa 10
Falkenstein 10
Haikou 9
Tianjin 9
Can Tho 8
Falls Church 8
Mountain View 8
Olalla 8
Taiyuan 8
Bangkok 7
Jakarta 7
Lanzhou 7
Yubileyny 7
Amsterdam 6
Atlanta 6
Brooklyn 6
Des Moines 6
Dhaka 6
Düsseldorf 6
Totale 7.109
Salva come PNG Salva come JPEG
Nome #
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 262
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 256
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 256
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 250
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 240
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 239
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 227
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 223
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 222
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 222
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 221
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 219
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 218
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 217
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 210
RALE051: a novel established cell line of sporadic Burkitt lymphoma 209
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 205
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 203
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 199
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 197
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 196
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 192
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 187
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 185
Treatment of colorectal cancer liver metastases 184
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 184
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 183
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 181
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 175
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 172
Bendamustine: role and evidence in lymphoma therapy, an overview. 170
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 168
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 167
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 165
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 165
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 164
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 162
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 161
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 161
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 158
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 156
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 155
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 152
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 151
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 149
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 147
SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 145
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 140
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 139
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. 136
The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma 135
Systemic adjuvant chemotherapy after resection of colorectal cancer metastases 130
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. 129
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. 128
IMPACT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL OF PATIENTS WITH KLATSKIN TUMOR 125
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOISTITUTIONAL EXPERIENCE. 124
Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. 119
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 111
The tratment of liver metastases from colorectal cancer: questions more than answers? 105
Phase I/II trial of continuous hepatic arterial infusion (HAI) of Irinotecan in patients with hepatocellular carcinoma (HCC). Preliminary results 98
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 90
Liver metastases from colorectal cancer 89
METRONOMIC CAPECITABINE IN ADVANCED PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): PRELIMINARY RESULTS. 88
Phase I/II trial of continuous hepatic arterial infusion (HAI) of irinotecan in patients with hepatocellular carcinoma (HCC). 87
null 75
Gemcitabine 28
Totale 11.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.682
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.682
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021467 0 0 0 0 0 0 0 0 0 0 0 467
2021/20221.385 196 53 104 144 108 71 45 71 48 89 245 211
2022/20231.484 197 200 83 189 96 120 29 80 196 47 113 134
2023/2024356 28 62 13 44 22 90 19 14 9 27 6 22
2024/20251.338 40 208 106 91 248 40 117 36 14 128 33 277
2025/20262.928 182 183 250 170 355 195 303 112 677 262 149 90
Totale 11.106